Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single and Multiple AscendingDose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-488 in Healthy Subjects and Patients With Psoriasis

Next Previous
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Single and Multiple AscendingDose Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ICP-488 in Healthy Subjects and Patients With Psoriasis

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ICP-488 (Primary)
  • Indications Psoriasis
  • Focus Adverse reactions
  • Sponsors InnoCare Pharma

    • Most Recent Events

    • 29 Aug 2023 According to an InnoCare Pharma media release, company accelerating the ongoing Phase I study of ICP-488 with psoriasis patients, and preliminary PoC is expected by the last quarter of 2023.
    • 04 Jul 2023 According to an InnoCare Pharma media release, in this phase I clinical trial, the single ascending doses (SAD) and multiple ascending doses (MAD) have been completed with ICP-488, demonstrating well-tolerated safety profile.
    • 04 Jul 2023 According to an InnoCare Pharma media release, the first psoriasis patient has been dosed in clinical trial of the Company's TYK2 (tyrosine kinase 2) JH2 allosteric inhibitor ICP-488 in China.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top